Projects
Enrolling Now!
Trial-Ready Cohort – Down Syndrome (TRC-DS)
The Trial-Ready Cohort-Down Syndrome, or TRC-DS, matches people with Down syndrome to clinical trials related to Alzheimer’s disease. TRC-DS routinely monitors study participants for any changes to their brain health or function over time through blood test and brain imaging to eventually match them with applicable Alzheimer’s disease clinical trials. Because participants are routinely evaluated, researchers can fast-track them for enrollment into qualifying clinical studies as soon as they are eligible and matched with one.
This project is funded by the National Institutes of Health’s INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) project, in partnership with ACTC-DS and ABC-DS.
Please visit https://www.trcds.org/ to know more.
ABATE Study: Join the fight against Alzheimer’s disease
People with Down syndrome often get Alzheimer’s disease (a type of dementia) when they get older. Dementia is a disease that causes memory loss and other thinking problems. Dementia due to Alzheimer’s occurs when a protein called amyloid builds up in the brain.
ABATE is an interventional study sponsored by AC Immune SA, a Swiss-based pharmaceutical company developing new treatments for neurodegenerative diseases, including Alzheimer’s disease. The study is testing a vaccine for Alzheimer’s disease in people with Down syndrome. The trial is being conducted by AC Immune in collaboration with the NIH-funded Alzheimer’s Clinical Trials Consortium – Down syndrome (ACTC-DS).
About 80 people with Down syndrome between 35 and 50 years old will take part in the ABATE study across 15 international sites in the US, the UK, and Spain.
If you or someone you know are interested and would like to learn more about the study, please visit www.Abate-study.com. You will find more information including the location and contact details of your nearest research center.
